Trial Profile
Effect of Prior Therapy With Nilotinib or Dasatinib on the Outcome After Allogeneic Stem Cell Transplantation for Patients With Chronic Myeloid Leukaemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Sep 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Dasatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Novartis
- 14 Aug 2019 Status changed from active, no longer recruiting to completed.
- 29 Aug 2014 New trial record